Andrew Firlik is a board-certified neurosurgeon turned venture capitalist at Jazz Venture Partners who combines hands-on surgical experience with an MD-MBA background and expertise in neurotechnology investing. He has founded multiple healthcare companies, holds numerous patents, and serves on boards of neuromodulation companies like Magnus Medical and Cadence Neuroscience, bringing clinical depth that most VCs lack.

• Deeply invested in neuroscience and brain health with a specific interest in how human consciousness and perception work. For example, backed baby nutrition company Yumi specifically because of its vital role in early childhood brain development and also highlighted Stanford research regarding brain stimulation as a highly effective treatment for depression.
• Highly focused on digital therapeutics and using software or non traditional technology to treat chronic medical conditions. Demonstrated this by celebrating Mahana Therapeutics securing FDA authorization for a digital treatment targeting irritable bowel syndrome and praising AppliedVR for successfully using virtual reality to treat lower back pain.
• Passionate about optimizing human performance through fitness, sleep tracking, and wellness tools. Frequently highlights consumer health innovations, such as the AI powered fitness app Freeletics, the biometric tracking capabilities of the Oura ring, and research showing how sleep states drive human energy production.
• Drawn to practical artificial intelligence and advanced technology that solves tangible problems in the real world. Expressed that purely theoretical deep learning often fails outside the lab and instead backed Robust AI specifically because they are building cognitive engines designed to productively coexist with human workers.
• Dedicated to advancing sophisticated biosciences and modern healthcare solutions that tackle rare diseases or increase biodiversity. Showed immense support for Colossal Biosciences advancing CRISPR technology to treat disease and AllStripes raising significant funding to accelerate clinical research for rare medical conditions.